Considerations and clinical utility of referral pathways for early detection of liver disease in at-risk populations

Table 7 Recommended re-evaluation strategies

	Interval	Early re-evaluation	Screening test
2021 EASL NIT clinical practice guideline	1-3 years		FIB-4
2021 AGA clinical care pathway	2-3 years		FIB-4
2023 AASLD practice guidance	2-3 years	After 1-2 years in individuals with T2DM or ≥ 2 metabolic risk factors	FIB-4
2024 EASL-EASD-EASO clinical practice guideline	1-3 years	Within 1 year when FIB-4 was indeterminate and management of comorbidities was intensified, whilst VCTE was not performed	FIB-4
2025 APASL clinical practice guideline	2-3 years		FIB-4, NFS

EASL: European Association for the Study of the Liver; NIT: Non-invasive test; AGA: American Gastroenterological Association; EASD: European Association for the Study of Diabetes; EASO: European Association for the Study of Obesity; APASL: Asian Pacific Association for the Study of Liver; AASLD: American Association for the Study of Liver Diseases; VCTE: Vibration controlled transient elastography; FIB-4: Fibrosis-4; T2DM: Type 2 diabetes mellitus; NFS: Nonalcoholic fatty liver disease fibrosis score.